The mission of the Bioinformatics Core (BIC) is to provide bioinformatics support for diverse approaches to cancer research in the COHCCC. The BIC collaborates with COHCCC governance committees to promulgate standards, optimize systems and minimize redundancy through continued integration of data, databases, applications and processes for enabling cost effective, collaborative, translational research. Since the last competitive renewal, the BIC has been working with experts in the field to establish a scalable high performance cyber-infrastructure equipped with close to 500 TB tiered storage repository with high bandwidth network connection, integrated cloud computing with internal TBs shared memory servers with more than 4000 hyper-threaded CPU and GPGPU processors, and external cloud computing to maximize both our infrastructure investment and provide infrastructure-on-demand. In addition, the BIC provides integrated laboratory information management systems (LIMS), which harbor research information portals shared among multiple core facilities (e.g., Functional Genomics and Genomic Sequencing, Drug Discovery and Structural Biology, Analytical Cytometry, Small Animal Imaging, and the developing Proteomics and Translational Research cores). The BIC also provides researchers with high-throughput biological data analysis, including integration with high-quality publicly available multi-disease, multi-cohort gene expression datasets. With highly-trained staff working in multidisciplinary teams, the BIC facilitates experimental design, QC/QA, data analysis, integration, annotation, dissemination, visualization and training for researchers. A new subscription-based chargeback policy was implemented in 2009 to offer tiered services to COHCCC members to be included in their grant proposals for adequate chargeback. The usage has nearly doubled from 45 subscribers in 2008 to 78 in 2010, and chargeback revenue has tripled from $46,487 in 2008 to $141,078 in 2010. Between 2007 and 2011, the BIC was used by a total of 88 principal investigators, 67 of whom are COHCCC members, and BIC staff collectively co-authored 52 peer-reviewed publications. The BIC's ongoing goal is to foster comprehensive bioinformatics support for researchers to enable collaborations among, basic, translational, clinical and population sciences researchers.

Public Health Relevance

The overall goal of the Bioinformatics Core facility is to provide COHCCC investigators with high-throughput biological data analysis tools, data management and cyber-infrastructure, and training to foster collaborations and develop modern computational techniques. This goal enables the Cancer Center's mission of developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-31
Application #
8764847
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
31
Fiscal Year
2014
Total Cost
$169,609
Indirect Cost
$68,652
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 1396 publications